Authors: ERMER JC BONI JP CEVALLOS WH DECLEENE S BURGHART P RUDNICK MR FRUNCILLO RJ BERNS JS COHEN RM

Citation: Jc. Ermer et al., BROMFENAC DISPOSITION IN PATIENTS WITH IMPAIRED KIDNEY-FUNCTION, Clinical pharmacology and therapeutics, 61(3), 1997, pp. 312-318

Authors: BURGHART P EVRARD J GRAILLE J UZZAN A

Citation: P. Burghart et al., WORLD CONFERENCE AND EXHIBITION ON OILSEE D AND EDIBLE OILS PROCESSING - ISTANBUL, OCTOBER 6-10, 1996, OCL. Oleagineux corps gras lipides, 3(6), 1996, pp. 403-403

Authors: EVRARD J BURGHART P CARRE P

Citation: J. Evrard et al., MODULATING CAKE QUALITY USING OIL TECHNOL OGY, OCL. Oleagineux corps gras lipides, 3(5), 1996, pp. 338-342

Authors: MENG X PARKER V BURGHART P DILEA C MALLETT S GONEN B CHIANG S

Citation: X. Meng et al., EFFECTS OF TOLRESTAT (T) ON PLASMA-GLUCOSE (G) LEVELS IN DIET-CONTROLLED, GLYBURIDE-CONTROLLED AND INSULIN-CONTROLLED (D, GLY AND I) DIABETICS, Clinical pharmacology and therapeutics, 57(2), 1995, pp. 154-154

Authors: KLAMERUS KJ VADIEI K BURGHART P NEEFE DL ZIMMERMAN JJ

Citation: Kj. Klamerus et al., ASCENDING, SINGLE-DOSE, SAFETY, TOLERANCE, AND PHARMACOKINETICS (PK) OF ENYL]-4-YL)METHYL]PYRIDO[2,3-D]PYRIMIDIN-7(6H)-ONE (ANA-756), Clinical pharmacology and therapeutics, 57(2), 1995, pp. 203-203

Authors: MENG X PARKER V TURNER M BURGHART P BATTLE M

Citation: X. Meng et al., EFFECT OF TOLRESTAT ON PHARMACOKINETICS (PK) OF DIGOXIN, Clinical pharmacology and therapeutics, 55(2), 1994, pp. 167-167